Dr. J. Eric McDuffie
|
About meDr. J. Eric McDuffie is heading the Mechanistic & Investigative Toxicology (MIT) team at Janssen’s La Jolla site. He joined Janssen in 2007, after a 7-year tenure at Pfizer’s Ann Arbor and Plymouth, MI sites. At Pfizer, he was responsible for providing investigative pathology and immunotoxicology support for Antibacterial, Cardiovascular/Atherosclerosis, Neuroscience, Dermatology, Inflammation, and Oncology projects. At Janssen, Dr. McDuffie’s team provides support to early discovery teams and work as part of a global group of preclinical safety assessment scientists to implement discovery toxicology strategies that enable rapid selection and progression of drug candidates to clinical trials, mostly for the Immunology and Neuroscience Therapeutic Areas. Dr. McDuffie has 17 years of experience in preclinical toxicology, including applications of novel toxicity mechanism-based assays and integrated models to support early target safety as well as to investigate potentially translatable organ-specific liabilities for late stage drug candidates. He earned a BS degree in Biology from Benedict College in Columbia, SC, a PhD degree in Pharmacology from Meharry Medical College in Nashville, TN and an MBA from the University of Phoenix, San Diego, CA. As postdoctoral research fellow at The University of Michigan Medical School in Ann Arbor, Michigan, he collaboratively investigated the role of pro- and anti-inflammatory cyto- and chemokines in liver, kidney, heart, and lung injury responses. He has co-authored over 30 peer‑reviewed manuscripts; presented numerous posters/platform presentations; authored book chapters; and served as book editor. Dr. McDuffie co-edited the benchmark book, Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers (2016). He is the Vice President-Elect to the Southern California Chapter of the Society of Toxicology (SCCSOT). Dr. McDuffie is also a Mentor in the 2017-2018 ToxMSDT Program which is funded by the NIH.
|
|
|
|